ProfileGDS5678 / 1429632_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 29% 29% 28% 28% 28% 27% 29% 40% 29% 29% 28% 28% 28% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6454627
GSM967853U87-EV human glioblastoma xenograft - Control 22.656529
GSM967854U87-EV human glioblastoma xenograft - Control 32.6535629
GSM967855U87-EV human glioblastoma xenograft - Control 42.5919828
GSM967856U87-EV human glioblastoma xenograft - Control 52.5989928
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7051528
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6663727
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6453929
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8856540
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6490529
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6397429
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6162728
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6478728
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6425628